X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (879) 879
Book / eBook (107) 107
Publication (61) 61
Book Review (39) 39
Book Chapter (9) 9
Conference Proceeding (3) 3
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (703) 703
index medicus (558) 558
female (449) 449
osteoporosis (342) 342
animals (319) 319
bone density conservation agents - pharmacokinetics (313) 313
bone density conservation agents - administration & dosage (310) 310
bone density conservation agents - therapeutic use (310) 310
male (263) 263
pharmacology & pharmacy (232) 232
bisphosphonates (193) 193
bone density conservation agents - pharmacology (193) 193
bone density conservation agents - adverse effects (185) 185
middle aged (185) 185
osteoporosis - drug therapy (179) 179
aged (169) 169
postmenopausal women (168) 168
diphosphonates - therapeutic use (154) 154
bone density - drug effects (152) 152
rats (139) 139
alendronate (135) 135
zoledronic acid (133) 133
bones (128) 128
research (125) 125
bone-mineral density (122) 122
diphosphonates - administration & dosage (121) 121
endocrinology & metabolism (116) 116
diphosphonates - pharmacokinetics (111) 111
osteoporosis, postmenopausal - drug therapy (111) 111
pharmacokinetics (110) 110
drug therapy (106) 106
therapy (105) 105
fractures (104) 104
bone density (102) 102
diphosphonates - adverse effects (100) 100
orthopedics (100) 100
treatment outcome (97) 97
health aspects (94) 94
adult (90) 90
medicine & public health (86) 86
oncology (86) 86
administration, oral (84) 84
bone (83) 83
women (82) 82
postmenopausal osteoporosis (80) 80
bone and bones - metabolism (78) 78
diphosphonates - pharmacology (76) 76
bone density conservation agents - chemistry (74) 74
care and treatment (74) 74
in-vitro (74) 74
risk factors (73) 73
bone neoplasms - secondary (72) 72
medicine (72) 72
mice (72) 72
dose-response relationship, drug (71) 71
drug administration schedule (70) 70
bone mineral density (69) 69
cancer (69) 69
bone diseases (66) 66
biological availability (65) 65
bone and bones - drug effects (65) 65
bisphosphonate (64) 64
rheumatology (63) 63
analysis (61) 61
double-blind (61) 61
rats, sprague-dawley (60) 60
aged, 80 and over (59) 59
dosage and administration (59) 59
bone remodeling - drug effects (58) 58
alendronate - pharmacokinetics (57) 57
surgery (56) 56
research article (54) 54
bone neoplasms - drug therapy (53) 53
density (52) 52
drug delivery systems (52) 52
risk (52) 52
denosumab (51) 51
double-blind method (51) 51
imidazoles - therapeutic use (50) 50
alendronate - administration & dosage (49) 49
diseases (49) 49
imidazoles - administration & dosage (48) 48
bone turnover (47) 47
calcium (47) 47
complications and side effects (47) 47
drugs (47) 47
risedronate (47) 47
bone resorption (46) 46
diagnosis (46) 46
endocrinology (46) 46
fractures, bone - prevention & control (46) 46
internal medicine (46) 46
breast cancer (45) 45
efficacy (45) 45
prevention (45) 45
ibandronate (44) 44
pharmacology (44) 44
review (44) 44
bone marrow (43) 43
breast-cancer (43) 43
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (86) 86
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Online Resources - Online (5) 5
Dentistry (Harry R Abbott) - Stacks (4) 4
Providence Healthcare - Stacks (4) 4
UTL at Downsview - May be requested (3) 3
Providence Healthcare - Reference (2) 2
Scarborough Hospital - Birchmount (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Credit Valley Hospital - Stacks (1) 1
Dentistry (Harry R Abbott) - Circulation Desk (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Holland Reference (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
Toronto East General Hospital - Online (1) 1
Toronto East General Hospital - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (961) 961
Japanese (13) 13
Spanish (6) 6
French (5) 5
German (4) 4
Norwegian (3) 3
Danish (2) 2
Russian (2) 2
Arabic (1) 1
Italian (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 1/2011, Volume 28, Issue 1, pp. 159 - 165
Journal Article
Osteoporosis International, ISSN 0937-941X, 6/2008, Volume 19, Issue 6, pp. 733 - 759
Bisphosphonates (BPs) are well established as the leading drugs for the treatment of osteoporosis. There is new knowledge about how they work. The differences... 
Bone resorption | Farnesyl pyrophosphate synthase | Fractures | Medicine & Public Health | Orthopedics | Rheumatology | Osteocytes | Hydroxyapatite | Bisphosphonates | Endocrinology | hydroxyapatite | BONE-MINERAL DENSITY | NITROGEN-CONTAINING BISPHOSPHONATES | bone resorption | RANDOMIZED-TRIAL | FRACTURE INTERVENTION TRIAL | DOSE-RESPONSE RELATIONSHIPS | FARNESYL DIPHOSPHATE SYNTHASE | INTRAVENOUS ZOLEDRONIC ACID | POSTMENOPAUSAL OSTEOPOROSIS | VERTEBRAL FRACTURES | ENDOCRINOLOGY & METABOLISM | ACTIVATION IN-VITRO | farnesyl pyrophosphate synthase | bisphosphonates | osteocytes | fractures | Bone Density Conservation Agents - pharmacokinetics | Osteocytes - drug effects | Bone and Bones - physiology | Humans | Bone Density Conservation Agents - therapeutic use | Diphosphonates - pharmacokinetics | Osteoporosis - drug therapy | Structure-Activity Relationship | Bone Density Conservation Agents - pharmacology | Bone and Bones - drug effects | Bone Resorption - prevention & control | Bone Density - drug effects | Animals | Osteoporosis - metabolism | Bone and Bones - metabolism | Diphosphonates - therapeutic use | Osteoporosis - physiopathology | Diphosphonates - pharmacology | Osteoclasts - drug effects | Post-translational modification | Medical colleges | Enzymes | Osteoporosis | Phosphonates | Hydroxylapatite | Lipids | Bone density | Pharmacology | Drug therapy
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 02/2014, Volume 54, Issue 2, pp. 168 - 178
ABSTRACTRomosozumab (formerly AMG 785/CDP7851) is a monoclonal antibody that blocks sclerostin from inhibiting osteoblast maturation and function. This... 
CDP7851 | romosozumab | bone mineral density | pharmacodynamics | pharmacokinetics | AMG 785 | sclerostin | Pharmacodynamics | Sclerostin | Bone mineral density | Romosozumab | Pharmacokinetics | PROTEIN | STRENGTH | OSTEOPOROSIS | DENSITY | GENE | PHARMACOLOGY & PHARMACY | SOST | Collagen Type I - blood | Peptides - blood | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Osteoporosis, Postmenopausal - metabolism | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antibodies, Monoclonal, Humanized - pharmacology | Peptide Fragments - blood | Aged, 80 and over | Female | Bone Density Conservation Agents - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Drug Administration Schedule | Antibodies, Monoclonal - pharmacology | Antibodies, Monoclonal - pharmacokinetics | Lumbar Vertebrae - drug effects | Procollagen - blood | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Osteoporosis, Postmenopausal - blood | Antibodies, Monoclonal - administration & dosage | Aged | Viral antibodies | Antibodies | Care and treatment | Dosage and administration | Postmenopausal women | Research | Osteoporosis | Men
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 03/2012, Volume 158, Issue 3, pp. 470 - 478
Journal Article
Journal Article